Jali Medical Logo

Inspiring Treatment Through Experience

Magstim TMS Therapy

As the pioneer of Transcranial Magnetic Stimulation (TMS), Magstim is recognized as a leader in diagnostic, research & therapy solutions.

Our Magstim TMS Therapy Products

Magstim Rapid2 Therapy: rTMS treatment

What is Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy?

rTMS treatment offers a new option for patients who have failed to respond, or are unable to undergo treatment with traditional pharmaceutical medication. The treatment of rTMS therapy has gained significant clinical traction and offers a new option for treatment of patients with drug resistant major depressive disorder (MDD).

rTMS has the following benefits

  • An effective non-drug treatment
  • Proven to treat MDD**
  • Safe, non-invasive therapy
  • No systemic side effects†
  • One-off capital purchase – no pay per use disposables
  • Built by Magstim, the pioneers of TMS
Magstim Rapid2 Therapy: Unmet Need

Unmet Need & Benefits

Globally, more than 350 million people of all ages suffer from depression[1]. By the year 2030, depression is predicted to become the number one cause of disability[2]. With traditional pharmaceutical options known to have associated side effects, clinical practitioners are increasingly turning to rTMS as a fast, effective treatment option for drug resistant MDD.

Proven Efficacy without Systemic Side Effects

In depression, over 80 separate trials and 4 separate large multicenter trials have been found to show significant improvements in depression following daily prefrontal rTMS for 3-6 weeks.

Magstim Rapid2 Therapy: Response Rates

Response Rates

A multisite, naturalistic, observational study of 307 patients, who had an average failure of 2.5 adequate medication trials, received an average of 28.3 TMS therapy sessions over an average of 42 days. This study showed that 58% of patients responded positively to TMS therapy and 37.1% of patients went into remission[3].

Treatment procedure

  • An initial session which includes the determination of the patient's individual stimulation level (motor threshold determination)
  • The recommended number of treatment sessions is 5 days per week for 6 weeks, followed by 6 sessions over the next 3 weeks.

Diagnosis and initial session are performed by a psychiatrist. The remaining treatment sessions are typically conducted by trained personnel.

The FDA cleared protocol for TMS Therapy treatment consists of repeated cycles of rTMS followed by rest periods (10 Hz; 4 second trains; 26 second wait; 75 trains for a total of 3,000 stimulations per treatment session at 120% motor threshold (37.5 min).

**The Rapid2 Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode (FDA 510k #K143531).

† There is an infrequent reported adverse effect of TMS is seizures. However, the estimated seizure risk is 0.003% of treatments, or 0.1% of patients [3]

[1] Depression Fact Sheet (2012). World Health Organisation.
[2] Global Burden of Disease Report (2006). Geneva, World Health Organisation
[3] Carpenter, L et al. Transcranial Magnetic Stimulation (TMS) for Major Depression: A multisite, naturalistic, observational study of acute treatment outcomes in clinical practice (2012)

Items marked with are investigational devices and for research use only. CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use.

About Jali Medical

Established in 1991, Jali Medical is a company at the cutting edge of the emerging field of non-invasive brain stimulation. We are proud to be the US distributor for the best magnetic and electrical nerve stimulation equipment and accessories available.

Contact Us
Jali Medical, Inc.
330 Bear Hill Road, Suite 303
Waltham, MA 02451
Phone(781) 376 0008 | (888) 959 JALI
Fax(781) 376 0808
Latest News
© 2018 Jali Medical, Inc. All rights reserved // site by M2P Design